Table 1.
Clinical characteristics of pediatric posterior fossa ependymoma
| Characteristics | Value (%) |
|---|---|
| Demographics | |
| No. of patients | 45 |
| Age, years, median (range) | 4 (1–17) |
| Gender, (female/male) | 12/33 |
| Tumor size, cm, median (range) | 4.7 (2.3–19.5) |
| Extent of surgery, GTR, n (%) | 21 (46.7) |
| Radiotherapy, yes, n (%) | 29 (64.4) |
| Chemotherapy, yes, n (%) | 12 (26.7) |
| Histology, n (%) | |
| WHO II | 10 (22.2) |
| WHO III | 35 (77.8) |
| Ki-67 index, n (%) | |
| < 20% | 20 (44.4) |
| ≥ 20% | 25 (55.6) |
| Molecular subgroups, n (%) | |
| EPN_PFA | 35 (77.8) |
| EPN_PFB | 10 (22.2) |
| Chromosome 1q | |
| Gain | 16 (35.6) |
| No gain | 29 (64.4) |
| 5hmC/(C + mC) × 100%, median (range) | 0.127 (0.028–0.341) |
| 5mC/(C + mC) × 100%, mean ± SD | 3.664 ± 0.426 |
| Recurrence, n (%) | 25 (55.6) |
| Death during follow-up, n (%) | 23 (51.1) |
| Follow-up period, months, median (range) | 38 (6–60) |
GTR gross total resection, 5hmC 5- hydroxymethylcytosine, 5mC 5-methylcytosine, C cytosine, EPN_PFA Group A posterior fossa ependymoma, EPN_PFB Group B posterior fossa ependymoma